Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 4/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12412644 | 0.89 | GRM5 (0.56) | GRM5NPC1GAAHPGDRAB9A | |
| SCHEMBL12412146 | 0.87 | GRM5 (0.54) | GRM5NPC1GAAHPGDRAB9A | |
| SCHEMBL12412357 | 0.87 | GRM5 (0.54) | GRM5NPC1GAAHPGDRAB9A | |
| SCHEMBL12412130 | 0.82 | GRM5 (0.71) | GRM5 | |
| SCHEMBL4481536 | 0.82 | CYP11B1 (0.69) | GRM5NPC1RAB9ATSHRSMN1; SMN2 | |
| SCHEMBL12412623 | 0.80 | GRM5 (0.64) | GRM5LMNATSHRSMN1; SMN2 | |
| SCHEMBL12412158 | 0.80 | GRM5 (0.53) | GRM5 | |
| SCHEMBL12412183 | 0.80 | GRM5 (0.65) | GRM5NPC1GAAHPGDRAB9A | |
| SCHEMBL12412630 | 0.79 | GRM4 (0.65) | GRM5NPC1GAAHPGDRAB9A | |
| SCHEMBL12412140 | 0.79 | GRM5 (0.59) | GRM5NPC1RAB9ATSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501757-B2 | Substituted phenylamine carboxamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same | VANDERBILT UNIVERSITY (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501757-B2 | Substituted phenylamine carboxamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same | VANDERBILT UNIVERSITY (US) | 2013-08-06 | — | — | US | disclosed |
| US-20110166158-A1 | SUBSTITUTED PHENYLAMINE CARBOXAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSITY | 2011-07-07 | — | — | US | disclosed |
| US-20110166158-A1 | SUBSTITUTED PHENYLAMINE CARBOXAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSITY | 2011-07-07 | — | — | US | disclosed |
| WO-2011035214-A1 | SUBSTITUTED PHENYLAMINE CARBOXAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSITY (US) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166158-A1 | SUBSTITUTED PHENYLAMINE CARBOXAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | GRM5, GRIK5, GRM2 | GRM5 1/4885NPC1 2517/4885GAA 2518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.